CIK细胞生物治疗联合化疗治疗晚期非小细胞肺癌的疗效观察

摘要

目的 观察CIK(cytokine induced killer)细胞生物治疗联合化疗治疗晚期肺癌的疗效.方法 采用回顾性分析的方式将鄞州钱湖医院及鄞州第二医院2013年2月~2015年1月收治的晚期肺癌患者65例,双盲、随机分为观察组34例和对照组31例.对照组患者单独给予化疗治疗,观察组在化疗基础上联合CIK细胞生物治疗,观察2组患者治疗前后血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)和癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)水平变化情况以及临床疗效对比.结果 ①观察组患者治疗后VEGF和MMP-9值分别为(298.67±36.49)ng/L、(1102.31±86.48)ng/mL,均优于对照组(459.19±45.28)ng/L、(1394.83±121.06)ng/mL,且差异有统计学意义(P<0.05).②观察组患者治疗后CEA和CYFR21-1值分别为(14.16±1.08)ng/mL、(4.45±0.45)ng/mL,均优于对照组(17.86±1.84)ng/mL、(5.76±0.64)ng/mL,且差异有统计学意义(P<0.05).③观察组患者治疗后总有效率94.18%明显高于对照组74.19%,且差异有统计学意义(P<0.05).结论 CIK细胞生物治疗联合化疗对晚期肺癌患者有一定的改善作用,值得临床进一步研究和应用.%Objective To observe the efficacy of advanced non-small cell lung cancer patients treated with CIK cell combined with chemotherapy.Methods65 cases of advanced lung cancer patients admitted in our hospital from February 2013 to January 2015 were retrospectively analyzed.The patients were randomly divided into observation group (34 cases) and control group (n=31).The levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9) and carcinoembryonic antigen (CEA) in the two groups were observed before and after treatment.The patients in the control group were treated with chemotherapy on the basis of chemotherapy.Cytokeratin 19 (CYFRA21-1) levels, and clinical efficacy.Results①The patients with VEGF and MMP-9 values after treatment (298.67±36.49)ng/L, (1102.31±86.48)ng/mL, than the control group (459.19±45.28)ng/L, (1394.83±121.06)ng/mL, and the difference was significant (P<0.05).②CEA and CYFR21-1 value patients in the observation group were (14.16±1.08) ng/mL, (4.45±0.45) ng/mL, than the control group (17.86±1.84) ng/mL, (5.76±0.64) ng/mL, and the difference was significant (P<0.05).③The total observation group was significantly higher than patients 94.18% 74.19% efficiency, and the difference was statistically significant (P<0.05).ConclusionCIK cell biological therapy combined with chemotherapy for advanced lung cancer patients with a certain improvement is worthy of further research and application.